"Rituximab & epcoritamab has shown impressive activity and manageable safety profile. We need longer follow-up to determine durability of responses, but R+Epcor could represent an attractive chemotherapy/ lenalidomide-free frontline treatment options for patients with FL." - Reid Merryman, MD #ASH25